Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
Copyright © 2021 Massachusetts Medical Society..
BACKGROUND: Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age.
METHODS: A phase 1, dose-finding study and an ongoing phase 2-3 randomized trial are being conducted to investigate the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in children 6 months to 11 years of age. We present results for 5-to-11-year-old children. In the phase 2-3 trial, participants were randomly assigned in a 2:1 ratio to receive two doses of either the BNT162b2 vaccine at the dose level identified during the open-label phase 1 study or placebo. Immune responses 1 month after the second dose of BNT162b2 were immunologically bridged to those in 16-to-25-year-olds from the pivotal trial of two 30-μg doses of BNT162b2. Vaccine efficacy against Covid-19 at 7 days or more after the second dose was assessed.
RESULTS: During the phase 1 study, a total of 48 children 5 to 11 years of age received 10 μg, 20 μg, or 30 μg of the BNT162b2 vaccine (16 children at each dose level). On the basis of reactogenicity and immunogenicity, a dose level of 10 μg was selected for further study. In the phase 2-3 trial, a total of 2268 children were randomly assigned to receive the BNT162b2 vaccine (1517 children) or placebo (751 children). At data cutoff, the median follow-up was 2.3 months. In the 5-to-11-year-olds, as in other age groups, the BNT162b2 vaccine had a favorable safety profile. No vaccine-related serious adverse events were noted. One month after the second dose, the geometric mean ratio of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing titers in 5-to-11-year-olds to those in 16-to-25-year-olds was 1.04 (95% confidence interval [CI], 0.93 to 1.18), a ratio meeting the prespecified immunogenicity success criterion (lower bound of two-sided 95% CI, >0.67; geometric mean ratio point estimate, ≥0.8). Covid-19 with onset 7 days or more after the second dose was reported in three recipients of the BNT162b2 vaccine and in 16 placebo recipients (vaccine efficacy, 90.7%; 95% CI, 67.7 to 98.3).
CONCLUSIONS: A Covid-19 vaccination regimen consisting of two 10-μg doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children 5 to 11 years of age. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.).
| Errataetall: |
CommentIn: N Engl J Med. 2022 Feb 10;386(6):604. - PMID 35045223 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:386 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 386(2022), 1 vom: 06. Jan., Seite 35-46 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Walter, Emmanuel B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 03.01.2023 published: Print-Electronic ClinicalTrials.gov: NCT04816643 CommentIn: N Engl J Med. 2022 Feb 10;386(6):604. - PMID 35045223 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2116298 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332900266 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332900266 | ||
| 003 | DE-627 | ||
| 005 | 20231225220528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2116298 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332900266 | ||
| 035 | |a (NLM)34752019 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Walter, Emmanuel B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04816643 | ||
| 500 | |a CommentIn: N Engl J Med. 2022 Feb 10;386(6):604. - PMID 35045223 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age | ||
| 520 | |a METHODS: A phase 1, dose-finding study and an ongoing phase 2-3 randomized trial are being conducted to investigate the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in children 6 months to 11 years of age. We present results for 5-to-11-year-old children. In the phase 2-3 trial, participants were randomly assigned in a 2:1 ratio to receive two doses of either the BNT162b2 vaccine at the dose level identified during the open-label phase 1 study or placebo. Immune responses 1 month after the second dose of BNT162b2 were immunologically bridged to those in 16-to-25-year-olds from the pivotal trial of two 30-μg doses of BNT162b2. Vaccine efficacy against Covid-19 at 7 days or more after the second dose was assessed | ||
| 520 | |a RESULTS: During the phase 1 study, a total of 48 children 5 to 11 years of age received 10 μg, 20 μg, or 30 μg of the BNT162b2 vaccine (16 children at each dose level). On the basis of reactogenicity and immunogenicity, a dose level of 10 μg was selected for further study. In the phase 2-3 trial, a total of 2268 children were randomly assigned to receive the BNT162b2 vaccine (1517 children) or placebo (751 children). At data cutoff, the median follow-up was 2.3 months. In the 5-to-11-year-olds, as in other age groups, the BNT162b2 vaccine had a favorable safety profile. No vaccine-related serious adverse events were noted. One month after the second dose, the geometric mean ratio of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing titers in 5-to-11-year-olds to those in 16-to-25-year-olds was 1.04 (95% confidence interval [CI], 0.93 to 1.18), a ratio meeting the prespecified immunogenicity success criterion (lower bound of two-sided 95% CI, >0.67; geometric mean ratio point estimate, ≥0.8). Covid-19 with onset 7 days or more after the second dose was reported in three recipients of the BNT162b2 vaccine and in 16 placebo recipients (vaccine efficacy, 90.7%; 95% CI, 67.7 to 98.3) | ||
| 520 | |a CONCLUSIONS: A Covid-19 vaccination regimen consisting of two 10-μg doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children 5 to 11 years of age. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Talaat, Kawsar R |e verfasserin |4 aut | |
| 700 | 1 | |a Sabharwal, Charu |e verfasserin |4 aut | |
| 700 | 1 | |a Gurtman, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Lockhart, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Paulsen, Grant C |e verfasserin |4 aut | |
| 700 | 1 | |a Barnett, Elizabeth D |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Flor M |e verfasserin |4 aut | |
| 700 | 1 | |a Maldonado, Yvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Pahud, Barbara A |e verfasserin |4 aut | |
| 700 | 1 | |a Domachowske, Joseph B |e verfasserin |4 aut | |
| 700 | 1 | |a Simões, Eric A F |e verfasserin |4 aut | |
| 700 | 1 | |a Sarwar, Uzma N |e verfasserin |4 aut | |
| 700 | 1 | |a Kitchin, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Cunliffe, Luke |e verfasserin |4 aut | |
| 700 | 1 | |a Rojo, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Kuchar, Ernest |e verfasserin |4 aut | |
| 700 | 1 | |a Rämet, Mika |e verfasserin |4 aut | |
| 700 | 1 | |a Munjal, Iona |e verfasserin |4 aut | |
| 700 | 1 | |a Perez, John L |e verfasserin |4 aut | |
| 700 | 1 | |a Frenck, Robert W |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Lagkadinou, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Swanson, Kena A |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Koury, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Mather, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Belanger, Todd J |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, David |e verfasserin |4 aut | |
| 700 | 1 | |a Türeci, Özlem |e verfasserin |4 aut | |
| 700 | 1 | |a Dormitzer, Philip R |e verfasserin |4 aut | |
| 700 | 1 | |a Şahin, Uğur |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen, Kathrin U |e verfasserin |4 aut | |
| 700 | 1 | |a Gruber, William C |e verfasserin |4 aut | |
| 700 | 0 | |a C4591007 Clinical Trial Group |e verfasserin |4 aut | |
| 700 | 1 | |a Acevedo, Armando |e investigator |4 oth | |
| 700 | 1 | |a Amisola, Rogelio |e investigator |4 oth | |
| 700 | 1 | |a Anderson, Evan |e investigator |4 oth | |
| 700 | 1 | |a Arimany Montañà, Josep Lluís |e investigator |4 oth | |
| 700 | 1 | |a Arora, Samir |e investigator |4 oth | |
| 700 | 1 | |a Baca Cots, Manuel |e investigator |4 oth | |
| 700 | 1 | |a Baker, Jeffrey |e investigator |4 oth | |
| 700 | 1 | |a Barnett, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Benun, Jacques |e investigator |4 oth | |
| 700 | 1 | |a Boppana, Suresh |e investigator |4 oth | |
| 700 | 1 | |a Butuk, David |e investigator |4 oth | |
| 700 | 1 | |a Caserta, Mary |e investigator |4 oth | |
| 700 | 1 | |a Casey, Janet |e investigator |4 oth | |
| 700 | 1 | |a Christensen, Shane |e investigator |4 oth | |
| 700 | 1 | |a Czajka, Hanna |e investigator |4 oth | |
| 700 | 1 | |a Day, James Christopher |e investigator |4 oth | |
| 700 | 1 | |a De Valle, Oscar |e investigator |4 oth | |
| 700 | 1 | |a Dever, Michael |e investigator |4 oth | |
| 700 | 1 | |a Domachowske, Joseph |e investigator |4 oth | |
| 700 | 1 | |a Eder, Frank |e investigator |4 oth | |
| 700 | 1 | |a Englund, Janet |e investigator |4 oth | |
| 700 | 1 | |a Fergie, Jaime |e investigator |4 oth | |
| 700 | 1 | |a Finn, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Fortuny Guasch, Clàudia |e investigator |4 oth | |
| 700 | 1 | |a Garcia-Diaz, Julia |e investigator |4 oth | |
| 700 | 1 | |a Garcia-Sicilia Lopez, Jose |e investigator |4 oth | |
| 700 | 1 | |a Garza, Homero |e investigator |4 oth | |
| 700 | 1 | |a Hartman, Aaron |e investigator |4 oth | |
| 700 | 1 | |a Heller, Robert |e investigator |4 oth | |
| 700 | 1 | |a Jennings, Timothy |e investigator |4 oth | |
| 700 | 1 | |a Kantele, Anu |e investigator |4 oth | |
| 700 | 1 | |a Karhusaari, Hanna |e investigator |4 oth | |
| 700 | 1 | |a Klein, Nicola |e investigator |4 oth | |
| 700 | 1 | |a Klein, Terry |e investigator |4 oth | |
| 700 | 1 | |a Kokko, Satu |e investigator |4 oth | |
| 700 | 1 | |a Kopinska, Elzbieta |e investigator |4 oth | |
| 700 | 1 | |a Korbal, Piotr |e investigator |4 oth | |
| 700 | 1 | |a Koski, Susanna |e investigator |4 oth | |
| 700 | 1 | |a Kuchar, Ernest |e investigator |4 oth | |
| 700 | 1 | |a Kulig, Karolina |e investigator |4 oth | |
| 700 | 1 | |a Laajalahti, Outi |e investigator |4 oth | |
| 700 | 1 | |a Leonard, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Li, Simon |e investigator |4 oth | |
| 700 | 1 | |a Majda-Stanislawska, Ewa |e investigator |4 oth | |
| 700 | 1 | |a Maldonado, Yvonne |e investigator |4 oth | |
| 700 | 1 | |a Marshall, Gary |e investigator |4 oth | |
| 700 | 1 | |a Martinón Torres, Federico |e investigator |4 oth | |
| 700 | 1 | |a Miranda Valdivieso, Mariano |e investigator |4 oth | |
| 700 | 1 | |a M Munoz, Flor |e investigator |4 oth | |
| 700 | 1 | |a Nachman, Sharon |e investigator |4 oth | |
| 700 | 1 | |a Natalini Martínez, Silvinia |e investigator |4 oth | |
| 700 | 1 | |a Ogbuagu, Onyema |e investigator |4 oth | |
| 700 | 1 | |a Ohnmacht, Richard |e investigator |4 oth | |
| 700 | 1 | |a Paavola, Pauliina |e investigator |4 oth | |
| 700 | 1 | |a Pajek, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Patel, Nehali |e investigator |4 oth | |
| 700 | 1 | |a Paulsen, Grant |e investigator |4 oth | |
| 700 | 1 | |a Peltonen, Lauri |e investigator |4 oth | |
| 700 | 1 | |a Peterson, James |e investigator |4 oth | |
| 700 | 1 | |a Rey, M Mildred |e investigator |4 oth | |
| 700 | 1 | |a Riesenberg, Robert |e investigator |4 oth | |
| 700 | 1 | |a Rojo, Pablo |e investigator |4 oth | |
| 700 | 1 | |a Salamanca de la Cueva, Ignacio |e investigator |4 oth | |
| 700 | 1 | |a Senders, Shelly |e investigator |4 oth | |
| 700 | 1 | |a Seppa, Ilkka |e investigator |4 oth | |
| 700 | 1 | |a Sharp, Stephan |e investigator |4 oth | |
| 700 | 1 | |a Sher, Lawrence |e investigator |4 oth | |
| 700 | 1 | |a A F Simões, Eric |e investigator |4 oth | |
| 700 | 1 | |a Simonsen, Kari |e investigator |4 oth | |
| 700 | 1 | |a Sipila, Marjaana |e investigator |4 oth | |
| 700 | 1 | |a Slade, Lance |e investigator |4 oth | |
| 700 | 1 | |a Slechta, Stacy |e investigator |4 oth | |
| 700 | 1 | |a Stryczyńska-Kazubska, Joanna |e investigator |4 oth | |
| 700 | 1 | |a Talaat, Kawsar |e investigator |4 oth | |
| 700 | 1 | |a Ukkonen, Benita |e investigator |4 oth | |
| 700 | 1 | |a Ulied Armiñana, Angels |e investigator |4 oth | |
| 700 | 1 | |a Vanchiere, John |e investigator |4 oth | |
| 700 | 1 | |a Walter, Emmanuel |e investigator |4 oth | |
| 700 | 1 | |a Wiedermann, Bernhard |e investigator |4 oth | |
| 700 | 1 | |a Wisman, Paul |e investigator |4 oth | |
| 700 | 1 | |a Zomcik, Anne |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 386(2022), 1 vom: 06. Jan., Seite 35-46 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:386 |g year:2022 |g number:1 |g day:06 |g month:01 |g pages:35-46 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2116298 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 386 |j 2022 |e 1 |b 06 |c 01 |h 35-46 | ||